Clinical progress of the standard treatment of cervical cancer

Abstract

Abstract:In recent years, the efficacy of cervical cancer treatment has been increasing gradually. It has got a basic consensus of the standard treatment mode for most cervical cancer, but further effort should be done to improve the treatment response of locally advanced cervical cancer and recurrent or metastatic cervical cancer. The efect of redical surgery and radiotherpy is the same to early cervical cancer. Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced cervical cancer. Chemotherapy combined with antiangiogenic targeted therapy can improve the survival of patients with recurrent or metastatic cervical cancer, while whether needing new adjuvant therapy or not, it asks for further investigation.

Key words:Uterine cervical neoplasms,Gynecologic surgical procedures,Radiotherapy ；Drug therapy,Molecular targeted therapy

BAI Jing. Clinical progress of the standard treatment of cervical cancer[J]. Journal of International Oncology, 2014, 41(12): 937-940.

References

［1］ Ueno S, Sudo T, Oka N, et al. Absence of human papillomavirus infection and activation of PI3KAKT pathway in cervical clear cell carcinoma［J］. Int J Gynecol Cancer, 2013, 23(6): 10841091. ［2］ Scatchard K, Forrest JL, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer［J］. Cochrane Database Syst Rev, 2012, 10: CD006469. ［3］ Sandadi S, Tanner EJ, KhouryCollado F, et al. Radical surgery with individualized postoperative radiation for stage IB cervical cancer: oncologic outcomes and severe complications［J］. Int J Gynecol Cancer, 2013, 23(3): 553558. ［4］ Zheng M, Huang L, He L, et al. Evaluation of the effects of type Ⅱ radical hysterectomy in the treatment of 960 patients with stage ⅠBⅡB cervical carcinoma: a retrospective study［J］. J Surg Oncol, 2011, 103(5): 435441. ［5］ Kundargi RS, Guruprasad B, Rathod PS, et al. Risk stratabased therapy and outcome in stage ⅠbⅡa carcinoma cervix: singlecentre tenyear experience［J］. Ecancermedicalscience, 2013, 7: 341. ［6］ Jeon HW, Suh DH, Kim K, et al. Lymphadenectomy alone is a feasible option in managing incidentallydetected earlystage cervical cancer after simple hysterectomy without intermediaterisk factors: an application of the concept of less radical surgery［J］. Anticancer Res, 2013, 33(11): 51355141. ［7］ Chai Y, Wang T, Wang J, et al. Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage ⅡB cervical cancer［J］. BMC Cancer, 2014,14: 63. ［8］ Mabuchi S, Okazawa M, Isohashi F,et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage ⅡB cervical cancer［J］. Gynecol Oncol, 2011, 123(2): 241247. ［9］ Rydzewska L,Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer［J］. Cochrane Database Syst Rev, 2012, 12: CD007406. ［10］ Wei LC, Wang N, Shi M, et al. Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma［J］. Onco Targets Ther, 2013, 6: 6774. ［11］ Lee DW, Lee KH, Lee JW, et al. Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stageⅡB cervical cancer?［J］. Int J Gynecol Cancer, 2013, 23(7): 13031310. ［12］ Prueksaritanond N, Chaisarn P, Yanaranop M. The efficacy of neoadjuvant paclitaxelcarboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage ⅠB2ⅡA cervical cancer［J］. J Med Assoc Thai, 2012, 95 Suppl 3: S5561. ［13］ Yin M, Zhao F, Lou G et al. The longterm efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advancedstage cervical cancer［J］. Int J Gynecol Cancer, 2011, 21(1): 9299. ［14］ Wen H, Wu X, Li Z, et al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage ⅠB2 to ⅡA cervical cancer［J］. Int J Gynecol Cancer, 2012, 22(2): 296302. ［15］ Rajasooriyar C, Van Dyk S, Bernshaw D, et al. Patterns of failure and treatmentrelated toxicity in advanced cervical cancer patients treated using extended field radiotherapy with curative intent［J］. Int J Radiat Oncol Biol Phys, 2011, 80(2): 422428. ［16］ Kidd EA, Siegel BA, Dehdashti F, et al. Clinical outcomes of definitive intensitymodulated radiation therapy with fluorodeoxyglucosepositron emission tomography simulation in patients with locally advanced cervical cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 77(4): 10851091. ［17］ Simpson DR, Song WY, Moiseenko V, et al. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): e8186. ［18］ Du XL, Tao J, Sheng XG, et al. Intensitymodulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy［J］. Gynecol Oncol, 2012, 125(1): 151157. ［19］ RenardOldrini S, Brunaud C, Huger S, et al. Dosimetric comparison between the intensity modulated radiotherapy with fixed field and Rapid Arc of cervix cancer［J］. Cancer Radiother, 2012, 16(3): 209214. ［20］ Tharavichitkul E, Chakrabandhu S, Wanwilairat S, et al. Intermediateterm results of imageguided brachytherapy and hightechnology external beam radiotherapy in cervical cancer: Chiang Mai University experience［J］. Gynecol Oncol, 2013, 130(1): 8185. ［21］ Mazeron R, Gilmore J, Dumas I, et al. Adaptive 3D imageguided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer［J］. Oncologist, 2013, 18(4): 415422. ［22］ Lee HJ, Kim YS, Shin SS, et al. Longterm outcomes of concomitant chemoradiotherapy incorporating highdoserate brachytherapy to treat locally advanced cervical cancer［J］. Tumori, 2012, 98(5): 615621. ［23］ Lim A, Sia S. Outcomes of chemoradiotherapy in cervical cancer—the Western Australian experience［J］. Int J Radiat Oncol Biol Phys, 2012, 82(4): 14311438. ［24］ Kato S, Ohno T, Thephamongkhol K, et al. Longterm followup results of a multiinstitutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia［J］. Int J Radiat Oncol Biol Phys, 2013, 87(1): 100105. ［25］ Rose PG, Sill MW, McMeekin DS, et al. A phase Ⅰstudy of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study［J］. Gynecol Oncol, 2012, 125(1):158162. ［26］ Chakraborty S, Patil N. Randomized clinical trial of weekly vs. triweekly cisplatinbased chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(4): 13201321. ［27］ Tummers P, Makar A, Vandecasteele K, et al. Completion surgery after intensitymodulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results［J］. Int J Gynecol Cancer, 2013, 23(5): 877883. ［28］ Legge F, Margariti PA, Lucidi A, et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures［J］. Acta Oncol, 2013, 52(1): 166173. ［29］ Tang J, Tang Y, Yang J, et al. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma［J］. Gynecol Oncol, 2012, 125(2): 297302. ［30］ Gao Y, Gao F, Liu Z, et al. Treatment results of incomplete chemoradiotherapy in locally advanced cervical cancer［J］. Onco Targets Ther, 2013, 6: 297302.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[3]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[6]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[7]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[8]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[9]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.
[11]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[12]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[13]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui.Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(12): 758-762.
[14]	Jiang Shan, Xu Ximing.Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(11): 688-695.
[15]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing.Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy[J]. Journal of International Oncology, 2023, 50(10): 600-607.